Retracted: Effects of MicroRNA‐19b on the Proliferation, Apoptosis, and Migration of Wilms’ Tumor Cells Via the PTEN/PI3K/AKT Signaling Pathway

Abstract

Wilms' tumor (WT) is a most common renal cancer that occurs among children, and microRNA-19b (miR-19b) usually participates in various human cancers. Importantly, the PTEN/PI3K/Akt signaling pathway plays a key role in cell apoptosis, growth and proliferation. Thus, our present study aims to investigate the effect of miR-19b on the PTEN/PI3K/Akt signaling pathway during WT cell proliferation, migration, and apoptosis. WT tissues and adjacent normal tissues from WT patients were collected. qRT-PCR was applied to detect miR-19b expression in both the WT tissues and the adjacent normal tissues, immunohistochemistry was applied to detect the protein expressions of PTEN, P13K, and p-Akt, SK-NEP-1 cells were divided into the blank, negative control (NC), miR-19b mimics and miR-19b inhibitors groups. MTT assay, propidium iodide (PI) staining, Annexin-V/PI double-staining, Transwell assay and Western blotting were performed to examine cell proliferation, cycle, apoptosis, migration, and invasion, and the protein expressions of PTEN, P13K, Akt, and p-Akt. Increased miR-19b expression, positive expression rates of P13K and Akt, decreased PTEN expression rate, a negative correlation between PTEN expression and tumor lymph node metastasis, and a positive correlation between the expression of P13K and Akt and the clinical stages were observed in the WT tissues. The miR-19b inhibitors group exhibited decreased cell proliferation, cell cycle progression, migration and invasion, and protein expressions of PI3K and p-Akt but increased PTEN protein expression compared with the blank and NC groups. Thus, inhibition of miR-19b suppresses the progression of WT by modulating the PTEN/PI3K/AKT signaling pathway. J. Cell. Biochem. 118: 3424-3434, 2017. © 2017 Wiley Periodicals, Inc.

Retracted: MicroRNA‐21 promotes glioma cell proliferation and inhibits senescence and apoptosis by targeting SPRY1 via the PTEN/PI3K/AKT signaling pathway

“…Previously, miR‐21 has been functionally demonstrated as an anti‐apoptosis factor in glioblastomas . Furthermore, the PTEN/PI3K/AKT signaling pathway plays a crucial role in cell growth, apoptosis, as well as proliferation in Wilms’ Tumor . However, there are few studies focusing on the mechanism of the role of miR‐21 in cell proliferation and apoptosis in glioma by targeting specific genes .…”

“…Tumor. 21 However, there are few studies focusing on the mechanism of the role of miR-21 in cell proliferation and apoptosis in glioma by targeting specific genes. 22 Therefore, the present study explored the expression of miR-21 in human glioma and its effect on the cell proliferation, senescence, and apoptosis by targeting SPRY1 through the PTEN/PI3K/AKT signaling pathway.…”

<p>Silencing of Peroxiredoxin 1 Inhibits the Proliferation of Esophageal Cancer Cells and Promotes Apoptosis by Inhibiting the Activity of the PI3K/AKT Pathway</p>

“…18 In the P13K/AKT pathway, following the activation of PI3K, 3,4,5-phosphatidylinositol trisphosphate phosphorylation is catalyzed and the protein kinase AKT is activated to promote the growth and proliferation of cells. 19 Our investigation of the specific mechanism of PRDX in EC cells showed that the effects of silencing PRDX1 alone and adding the P13K/AKT pathway inhibitor alone were similar. Both interventions inhibited the proliferation and clonality of ESCC cells and increased the rate of apoptosis.…”

Role of PI3K/AKT pathway in cancer: the framework of malignant behavior

“…To a further extent, PI3K/AKT/mTOR is identified as a highly enriched pathway in translocation RCC with TFE3 fusion (TFE3-tRCC) by miRNA microarray analysis [258]. Besides that PIK3R1 regulates EMT and stem-like phenotype of RCC cells through the AKT/GSK3β/CTNNB1 pathway [259], FoxO, PKCε, TPD52, NOTCH1, ETS2, miR-19b, -122, -182, -193a-3p, -195, and -224, as well as LncRNA MALAT1, TP73-AS1 and HOTTIP modulate proliferation, apoptosis, invasion, metastasis, or EMT via PI3K/ AKT pathway [260][261][262][263][264][265][266][267][268][269][270][271][272]. However, only a few of clinical trials of PI3K/AKT inhibitors in touch try to offer hope for KC patients (Tables 2 and 3).…”